ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 98 filers reported holding ASCENDIS PHARMA A/S in Q3 2018. The put-call ratio across all filers is 1.39 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $16,972,000 | -46.4% | 144,194 | -71.5% | 0.65% | -48.6% |
| Q4 2018 | $31,644,000 | +39.6% | 505,098 | +57.8% | 1.27% | +56.0% |
| Q3 2018 | $22,675,000 | -29.3% | 320,000 | -33.7% | 0.81% | -28.0% |
| Q2 2018 | $32,094,000 | +1.7% | 482,467 | 0.0% | 1.13% | +3.1% |
| Q1 2018 | $31,553,000 | -0.2% | 482,467 | -38.9% | 1.09% | -12.1% |
| Q4 2017 | $31,607,000 | +2.6% | 789,000 | -7.2% | 1.24% | -10.4% |
| Q3 2017 | $30,813,000 | +164.6% | 850,000 | +102.6% | 1.39% | +123.5% |
| Q2 2017 | $11,644,000 | -55.2% | 419,453 | -54.9% | 0.62% | -38.1% |
| Q1 2017 | $26,018,000 | +22.4% | 929,226 | -11.5% | 1.00% | +14.8% |
| Q4 2016 | $21,252,000 | +5659.3% | 1,050,000 | +4933.8% | 0.87% | +7183.3% |
| Q2 2015 | $369,000 | -89.4% | 20,859 | -89.6% | 0.01% | -89.3% |
| Q1 2015 | $3,470,000 | – | 200,000 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |